title: The preventive effect of halofuginone on posterior glottic stenosis in a rabbit model.
abstract: OBJECTIVE
  The aim of this study was to investigate the preventive effect of halofuginone on posterior glottic stenosis (PGS) in an animal model.
  
  
  METHODS
  A randomized, controlled animal study.
  
  
  METHODS
  Sixteen male New Zealand White rabbits were used for this study. After the mucosa of posterior glottis was removed for producing PGS, the study group (eight rabbits) was given intraperitoneal halofuginone at 0.1 mg/kg/day for 4 weeks and saline was injected into peritoneum in the control group. At 4 weeks after injury, postsurgical changes of posterior glottis were evaluated by gross and histologic examination.
  
  
  RESULTS
  PGS was induced by the mucosal stripping of the posterior glottis. The halofuginone-treated group showed less scarring and granulation tissue formation. Also, the degree of synechia was significantly less than that of control group. Histologic analysis showed the decreased fibrosis in the halofuginone-treated group.
  
  
  CONCLUSIONS
  This study suggests that halofuginone can be helpful in preventing PGS after laryngeal injury.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Cancer Research Institute, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
authors.forename: Yeo-Hoon
authors.initials: YH
authors.lastname: Yoon
authors.forename: Ki-Sang
authors.initials: KS
authors.lastname: Rha
authors.forename: Bon Seok
authors.initials: BS
authors.lastname: Koo
authors.forename: Jae Yong
authors.initials: JY
authors.lastname: Park
authors.forename: Yong Min
authors.initials: YM
authors.lastname: Kim
authors.forename: Yong Ho
authors.initials: YH
authors.lastname: Park
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005355:Fibrosis; D005931:Glottis / Q000473:pathology; D007274:Injections, Intraperitoneal; D007829:Laryngostenosis / Q000517:prevention & control*; D008297:Male; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D052999:Quinazolinones / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation
chemical_list: D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D052999:Quinazolinones; C010176:halofuginone